Fairfield University

DigitalCommons@Fairfield
Biology Faculty Publications

Biology Department

2011

A Mediterranean Low-Glycemic-Load Diet alone or in Combination
with a Medical Food Improves Insulin Sensitivity and Reduces
Inflammation in Women with Metabolic Syndrome
Jennifer L. Jones
Follow
and additional works at: https://digitalcommons.fairfield.edu/biology-facultypubs
Danielathis
Ackerman

Copyright 2011 SCIENCEDOMAIN International
Jacqueline Barona
Copyright 2011 The copyrights of all papers published in this journal are retained by the
Mariana Calle
respective
authors as per the 'Creative Commons Attribution License'
(http://creativecommons.org/licenses/by/3.0/).
Catherine J. Andersen
Fairfield University, candersen@fairfield.edu

Peer Reviewed

See next page for additional authors

Repository Citation

Jones, Jennifer L.; Ackerman, Daniela; Barona, Jacqueline; Calle, Mariana; Andersen, Catherine J.; Kim,
Jung Eun; Volek, Jeff S.; McIntosh, Mark; Najm, Wadie; Lerman, Robert H.; and Fernandez, Maria Luz, "A
Mediterranean Low-Glycemic-Load Diet alone or in Combination with a Medical Food Improves Insulin
Sensitivity and Reduces Inflammation in Women with Metabolic Syndrome" (2011). Biology Faculty
Publications. 37.
https://digitalcommons.fairfield.edu/biology-facultypubs/37

Published Citation
Jones, Jennifer L., Daniela Ackermann, Jacqueline Barona, Mariana Calle, Catherine Andersen, Jung Eun Kim, Jeff
S. Volek, Mark McIntosh, Wadie Najm, Robert H. Lerman, and Maria Luz Fernandez. "A Mediterranean LowGlycemic-Load Diet alone or in Combination with a Medical Food Improves Insulin Sensitivity and Reduces
Inflammation in Women with Metabolic Syndrome." British Journal of Medicine & Medical Research 1, no.4 (2011):
356-370.
This item has been accepted for inclusion in DigitalCommons@Fairfield by an authorized administrator of
DigitalCommons@Fairfield. It is brought to you by DigitalCommons@Fairfield with permission from the rightsholder(s) and is protected by copyright and/or related rights. You are free to use this item in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses, you need to obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/or on the work itself. For more information, please contact digitalcommons@fairfield.edu.

Authors
Jennifer L. Jones, Daniela Ackerman, Jacqueline Barona, Mariana Calle, Catherine J. Andersen, Jung Eun
Kim, Jeff S. Volek, Mark McIntosh, Wadie Najm, Robert H. Lerman, and Maria Luz Fernandez

This article is available at DigitalCommons@Fairfield: https://digitalcommons.fairfield.edu/biology-facultypubs/37

British Journal of Medicine & Medical Research
1(4): 356-370, 2011
SCIENCEDOMAIN international
www.sciencedomain.org

A Mediterranean Low-Glycemic-Load Diet
alone or in Combination with a Medical Food
Improves Insulin Sensitivity and Reduces
Inflammation in Women with Metabolic
Syndrome
Jennifer L. Jones1, Daniela Ackermann1, Jacqueline Barona1,
Mariana Calle1, Catherine Andersen1, Jung Eun Kim1, Jeff S. Volek1,
Mark McIntosh2, Wadie Najm3, Robert H. Lerman4
and Maria Luz Fernandez1*
1

Department of Nutritional Sciences, University of Connecticut, Storrs, Connecticut, USA.
2
Departmemt of Emergency Medicine, University of Florida, Jacksonville, Florida, USA.
3
Department of Medicine, University of California, Irvine, California, USA.
4
Metagenics Inc., Gig Harbor, WA.

th

Research Article

Received 15 July 2011
th
Accepted 13 August 2011
th
Online Ready 24 August 2011

ABSTRACT
Aim: To determine the effects of a Mediterranean-style low-glycemic load diet alone or
in combination with a medical food (MF) on insulin resistance and inflammation in
women with metabolic syndrome (MetS).
Study design: Two groups, Parallel study with control.
Place and Duration of Study: Department of Nutritional Sciences, University of
Connecticut, Storrs, CT; Department of Emergency Medicine, University of Florida,
Jacksonville, FL; Department of Medicine, University of California, Irvine, CA. The study
was carried out from September of 2009 to May 2010.
Methodology: Eighty three women (20-75 y) with MetS. Participants were randomly
allocated to consume diet alone (control group) or the diet plus the MF (MF group) for
12 wk. Body composition was measured at baseline, week 8 and week 12 by use of
bioelectrical impedance in all participants while Dual-emission X-ray absorptiometry was
___________________________________________________________________________________________
*Corresponding author: Email: maria-luz.fernandez@uconn.edu;
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used for 37 of the subjects. Insulin resistance, plasma insulin, leptin, adiponectin and
the inflammatory cytokines, tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), adhesion
molecules, sICAM-1 and sVCAM-1, were measured at the same time points.
Results: Independent of group allocation, women had decreases in body mass index (p
< 0.0001) and body and trunk fat (p < 0.0001). Plasma insulin, insulin resistance, and
leptin were also significantly decreased over time (p < 0.0001), while plasma
adiponectin levels did not change. Regarding inflammatory markers, significant
reductions were found in TNF-α (p < 0.0001) and sICAM-1 levels (p < 0.001), but not in
IL-6 or sVCAM-1. At 12 wk, sICAM was reduced only in the MF group (p<0.05 vs
control).
Conclusion: A Mediterranean-style diet, in combination with a MF, are a viable option
to decrease factors associated with increased risk for type 2 diabetes and coronary
heart disease.

Keywords: Metabolic syndrome; mediterranean diet; glycemic load; insulin; inflammation;
body composition;
This trial was registered at clinicaltrials.gov as NCT01010841.

ABBREVIATIONS
BMI: body mass index; BP: blood pressure; CVD: cardiovascular disease; DEXA: dualenergy X-ray absorptiometry; HDL-C: HDL cholesterol; ICAM: Intracellular adhesion
molecule; IL-6: interleukin-6; LDL-C: LDL cholesterol; MetS: Metabolic syndrome; NHANES:
National Health and Nutrition Examination Survey; T2D: type 2 diabetes; TNF-α: tumor
necrosis alpha; VCAM: vascular cell adhesion molecule-1 WC: waist circumference; WC:
waist circumference.

1. INTRODUCTION
Insulin resistance, the diminished capacity of a cell to respond to insulin action, has been
established as a primary underlying cause of metabolic syndrome (MetS) development
(Lann, Gallagher et al. 2008; Gallagher, Leroith et al., 2010; Maheshwari and Thuluvath,
2011). An individual is classified as having MetS if 3 of the following criterion are met:
hyperglycemia, high waist circumference (WC), elevated blood pressure (BP), elevated
triglycerides (TG), and low high-density lipoprotein cholesterol (HDL-C) (Alberti, Eckel et al.
2009). According to the National Health and Nutrition Examination Survey (NHANES) 20032006, approximately one-third of the US adult population is affected by MetS, and this
significantly increases the risk for developing cardiovascular disease (CVD) and type 2
diabetes (T2D) (Ervin 2009).
While insulin resistance is often considered the causal feature for development of MetS,
abdominal obesity is also a major contributor and the two components are clearly related
(Després, 2006; Després, Lemieux et al., 2008; Westphal, 2008; Reddy, Singh et al., 2010).
Adipose tissue is considered an active endocrine organ (Wozniak, Gee et al., 2009; Han and
Lean, 2011), responsible for secreting biologically active molecules, collectively termed
‘adipokines’ (Caruso, Balistreri et al., 2010). When adipose tissue is excessive, secretion of
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adipokines such as adiponectin, leptin, interleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-α) can be negatively altered (Lago, Dieguez et al., 2007; Lago, Gómez et al., 2009),
which can in turn influence energy regulation and inflammation (Han and Lean, 2011).
Adiponectin, an insulin sensitizer with anti-inflammatory properties, tends to be decreased in
obesity and MetS (Ryo, Nakamura et al. 2004; Huang 2009). Leptin is important for
regulation of appetite and energy balance. In obese individuals, despite elevated leptin
concentrations, sensitivity to this molecule has been shown to decrease (Gnacińska,
Małgorzewicz et al., 2009). Proinflammatory adipokines, IL-6 and TNF-α, also tend to be
upregulated in obesity, and these molecules have a role in insulin resistance and endothelial
dysfunction (Ryo, Nakamura et al. 2004; Maury and Brichard 2010; Van Linthout, ForystLudwig et al. 2010). These inflammatory mediators alter insulin sensitivity via action on
nuclear factor kappa B (NFкB) and jun N-terminal kinase (JNK) pathways, and they facilitate
expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1), which both play a role in atherogenesis (Lyon, Law et al., 2003;
Shoelson, Herrero et al., 2007). Obesity has also been associated with macrophage
accumulation in adipose tissue, and this could further contribute to the production of
proinflammatory cytokines (Weisberg, McCann et al., 2003).
The central focus to treat inflammation, excess abdominal fat stores, and insulin resistance
that compose MetS, remains lifestyle modification. Various researchers have highlighted the
potential efficacy of adherence to a Mediterranean-style diet for treatment of MetS
characteristics (Babio, Bulló et al., 2009; Sofi, 2009; Kastorini, Milionis et al., 2011).
Epidemiological data suggest that prevalence of MetS tends to be associated with dietary
patterns that contain excessive amounts of high glycemic index foods (Baxter, Coyne et al.
2006). Therefore, our aim was to examine the impact of a low-glycemic-load Mediterraneanstyle diet on specific MetS variables, namely inflammation, insulin resistance, and obesity.
Additionally, our objective was to assess whether a medical food (MF), containing rho isoalpha acids from hops (Humulus lupulus L.) and proanthocyanidins from acacia (Acacia
nilotica), which may modulate insulin-signaling and inflammatory pathways (Lerman, Minich
et al., 2008), provided further benefits. We hypothesized that following this dietary
intervention would result in similar weight loss for all participants, but the group consuming
the MF would have greater improvements in insulin sensitivity and present a better
inflammatory profile.

2. METHODS
2.1 Materials
®

O

The medical food (UltraMeal Plus 360 ) was provided by Metagenics, Inc (Gig Harbor,
WA), in powdered form. Kits to measure adiponenctin, sICAM, sVCAM, TNF-α and IL-6
were obtained from Millipore (Billerica, MA).

2.2 Study Population
Women were recruited at three sites (University of Connecticut, Storrs, CT; University of
Florida, Jacksonville, FL and University of California, Irvine, CA). To be eligible for
participation, women had to be between the ages of 20 and 75 years with a BMI between 25
2
and 45 kg/m . In addition, they had to have LDL-C ≥ 100 mg/dL (2.59 mmol/L), TG ≥ 150
mg/dL (1.70 mmol/L), and meet two of the four remaining criteria for MetS according to
NCEP-ATP-III criteria [HDL-C < 50 mg/dL (1.30 mmol/L), fasting plasma glucose > 100

358

British Journal of Medicine & Medical Research, 1(4): 356-370, 2011

mg/dL (5.55 mmol/L), blood pressure (BP) > 130/85 mm Hg, and WC > 88 cm) (ATP, (2002).
Main exclusion criteria included heart, liver, or kidney disease and use of hypoglycemic or
cholesterol-lowering agents. Potential participants provided informed consent during
screening and before the study began. The women also provided a medical history prior to
participation. Study protocols and the procedures to obtain consent forms were approved by
the Institutional Review Board at each respective site.

2.3 Study Design
After entrance criteria were met and consent was obtained, women were randomly allocated
to the control group or the medical food (MF) group. Both groups were given detailed
instructions to consume a modified Mediterranean-style, low-glycemic-load diet for the
duration of the 12-week intervention. Women in the MF group consumed the same diet plus
a powdered beverage form of a medical food containing soy protein, plant sterols, rho isoalpha acids, and Acacia proanthocyanidins, mixed into water, twice each day for 12 weeks.
Participants came on-site for a baseline visit and returned at weeks 2, 4, 6, 8, 10, and 12 for
follow-up visits. Compliance with MF intake guideline was assessed by weighing the unused
powder every 2 weeks.

2.4 Diet and Exercise Description
Participants were invited to an on-site meeting 1 week prior to the start of the study, at which
time an instructional DVD was viewed and detailed dietary booklets were distributed
summarizing dietary guidelines, lists of suitable foods, suggested serving sizes, and recipes.
Subjects were also instructed on how to complete a detailed food record that included 2
weekdays and one weekend day. The dietary approach was parallel to that designed by
Schiltz et al. (Schiltz, Minich et al., 2009). Subjects were advised to follow a Mediterraneanstyle diet with emphasis on intake of legumes, fish and lean meats. In addition, specific
limitations were placed on intake of grains (1 serving per day) and alcohol (an optional 1
serving per day). Lastly, natural and artificial sweeteners were excluded from the diet. The
women were not instructed to restrict caloric intake. A 3-day food record was obtained at
baseline (to assess habitual dietary intake) and every 2 weeks (to assess dietary compliance
and nutrient intake). The participants met with a Registered Dietitian at each visit for diet
counseling. Subjects were asked to maintain their normal level of physical activity for the
entirety of the intervention and 7-day exercise logs were collected to measure compliance
with this instruction.

2.5 Data Collection
Following a 12-hour overnight fast, 60 mL of blood were collected into EDTA tubes at
baseline, week 8, and week 12. Plasma was separated by centrifugation at 2000 x g: 20 min
at 4°C. The plasma was aliquoted to cryotubes and stored at -80 °C and later sent to a
certified laboratory (Northwest Lipid Research Laboratories, Seattle, WA) for analysis of
insulin, or used at the University of Connecticut for analysis of adipokines and inflammatory
markers.

2.6 BMI and Body Composition
At each visit, body weight was measured to the nearest 0.1 kg on a calibrated digital scale,
2
and BMI was calculated (kg/m ). At baseline, week 8 and week 12, bioelectrical impedance
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analysis (BIA) was used to assess body composition, utilizing an Impedimed DF 50 (Xitron
Technologies, San Diego, CA) at all sites. In addition to the BIA, the University of
Connecticut and the University of California, Irvine, determined whole body and regional
body composition using fan-beam dual-energy X-ray absorptiometry (DEXA) (Prodigy,
Lunar Advance Corporation, Madison, WI). Analyses were performed by a technician at the
respective sites (MF: n = 18, control: n = 17).

2.7 Plasma Insulin and Insulin Resistance
Plasma insulin was measured by a chemiluminescent, immunoassay using the DPC
Immulite 2000 (Diagnostics Products Corporation, Nutley, NJ) at Northwest Lipid Research
Laboratories (Seattle, WA). Insulin resistance was calculated using the homeostasis model
assessment (HOMA) equation ([fasting insulin (µU/ml) x fasting glucose (mmol/l)]/22.5)
(Muniyappa, Lee et al., 2008).

2.8 Fasting Adiponectin, sVCAM-1, and sICAM-1
Fasting plasma was used to measure concentrations of adiponectin, sVCAM-1, and sICAM1 in duplicate using the Milliplex Human CVD Panel 1 (City, State). The samples were
diluted 1:100 and antibody-immobilized beads specific for each analyte were used for
®
®
simultaneous quantification with xMAP technology on the Luminex IS 200 system (Austin,
TX).

2.9 Fasting IL-6, TNF-α, and Leptin
Fasting plasma was used to measure concentrations of IL-6, TNF-α, and leptin in duplicate
®
®
using the Milliplex Human Cytokine kit and xMAP technology on the Luminex IS 200
system (Austin, TX). Specific antibody-immobilized beads were used to simultaneously
quantify IL-6, TNF-α, and leptin.

2.10 Statistical Analysis
Repeated measures analysis of variance (ANOVA) was used to compare the control and MF
groups over time. The repeated measure was the individual’s response to the intervention
over time and the control vs. the MF served as the between subject factors. SPSS 12.0 for
Windows (SPSS, Inc., Evanston, IL) was used and results were considered significant with a
p < 0.05.

3. RESULTS
3.1 BMI and Body Composition
Participants in both groups had significant decreases in BMI from baseline to the end of the
12-week intervention (p < 0.0001, Table 1), but no differences were observed between the
groups. Examination of BIA measurements revealed that fat mass, in kg and as a
percentage of total body weight, decreased significantly over time (p < 0.0001 Table 1),
regardless of group categorization. Likewise, fat free mass in kg decreased in both groups (p
< 0.0001) while percent of fat free mass increased also for both groups (p < 0.001, Table 1),
with no differences noted between groups.
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Table 1. Body mass index (BMI) and body composition as measured by bioelectrical impedance analysis of women
allocated to the Medical Food group (n = 42) or the Control group (n = 41) at baseline, week 8 and week 12 of the
1
intervention
BMI
kg/m

Fat Free Mass
2

Medical Food Group
a
Baseline
34.9 ± 6.1
b
Week 8
33.1 ± 5.5
b
Week 12
32.5 ± 5.8
Control Group
a
Baseline
35.0 ± 5.5
b
Week 8
33.1 ± 5.0
b
Week 12
32.7 ± 5.1
Time Effect
P < 0.0001

Fat Mass

Fat Free Mass

kg

Fat Mass

%
a

41.8 ± 10.5
b
38.4 ± 10.6
b
37.7 ± 10.4

a

39.4 ± 9.0
b
36.1 ± 9.2
b
35.3 ± 9.5
P < 0.0001

50.7 ± 5.7
b
49.4 ± 5.4
b
48.8 ± 5.2
50.7 ± 5.8
b
49.7 ± 5.6
b
49.5 ± 5.6
P < 0.0001

a

a

55.7 ± 4.3
b
57.4 ± 5.9
b
57.6 ± 5.7

a

44.2 ± 4.3
b
42.6 ± 5.9
b
42.4 ± 5.7

a

43.9 ± 3.5
b
42.2 ± 5.2
b
41.7 ± 5.8
P < 0.001

56.0 ± 3.6
b
57.8 ± 5.4
b
58.4 ± 6.1
P < 0.0001

a

a

1

Values are expresses as mean ± SD. No diet effects or interactive effects were found for these variables.
Values with different superscripts are significantly different as compared to baseline.
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Fig. 1. Percent Body Fat (A) and Percent Trunk Fat (B) calculated by DEXA at baseline week 8 and week 12 for women
allocated to Medical Food (n = 18) or Control (n = 17). ** p < 0.0001.
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Fig. 2. Body Fat Weight (A) and Trunk Fat Weight (B) calculated by DEXA at baseline week 8 and week 12 for women
allocated to Medical Food (n = 18) or Control (n = 17). ** p < 0.0001.
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The University of Connecticut and the University of California, Irvine, had access to DEXA,
which allowed measurements of body fat and trunk fat for a subset of subjects (MF: n = 18,
control: n = 17). Percent body fat and percent trunk fat decreased in both groups, with no
differences between groups (p < 0.0001; A and B, respectively, Figure 1).
Similarly, there were no differences between groups in relation to the significant reductions
observed in kg of body fat and trunk fat (p < 0.0001, A and B, respectively, Figure 2).

3.2 Insulin and Insulin Resistance
Plasma insulin levels decreased in both groups over the course of the 12-week intervention,
independent of group allocation (p < 0.0001, Table 2). HOMA scores were utilized to assess
insulin resistance, and both groups displayed reductions in this variable (p < 0.0001, Table
2), with no between-group differences noted.
Table 2. Changes in insulin and insulin resistance as measured by HOMA ofwomen
allocated to the Medical Food group (n = 42) or the Control group (n = 41) at baseline,
1
week 8 and week 12 of the Intervention
Insulin

HOMA*

µIU/mL
Medical Food Group
Baseline
Week 8
Week 12
Control Group
Baseline
Week 8
Week 12
Time Effect

16.9 ± 9.4
b
12.3 ± 6.0
b
12.6 ± 7.6

a

4.25 ± 2.93
b
3.01 ± 1.57
b
2.99 ± 1.91

a

4.12 ± 2.40
b
2.84 ± 1.30
b
3.01 ± 1.58
P < 0.0001

16.6 ± 9.4
b
11.8 ± 5.4
b
12.2 ± 5.7
P < 0.0001

a

a

1

Values are expresses as mean ± SD. No diet effects were found for these variables.
Values with different superscripts are significantly different as compared to baseline.

3.3 Adipokines and Inflammatory Markers
Plasma adiponectin levels did not change significantly in either group over time (Table 3).
However, changes were observed in plasma levels of leptin (p < 0.0001, Table 3), although
the changes were not significantly different between groups. While plasma levels of IL-6 did
not change significantly in either group (Table 3), there were differences observed over time
for plasma TNF-α (p < 0.0001, Table 3); however, these were not different between groups
at the end of the intervention. sICAM-1 decreased in the MF group over time (p < 0.001,
Table 3), while levels in the control group were not different from baseline in either week 8 or
12 (Table 3). No significant changes in sVCAM-1 were measured for either group (Table 3).
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Table 3. Changes in adiponectin, tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), soluble intercelluar adhesion molecule1 (ICAM)-1 and soluble vascular cell adhesion molecule (VCAM)-1 of women allocated to the Medical Food group (n = 42) or
1
the Control group (n = 41) at baseline, week 8 and week 12 of the intervention
Adiponectin
mg/L
Medical Food Group
a
Baseline
15.2 ± 7.9
a
Week 8
15.7 ± 6.8
a
Week 12
15.0 ± 10.7
Control Group
a
Baseline
14.2 ± 6.8
a
Week 8
13.8 ± 6.0
a
Week 12
14.8 ± 6.3
Time Effect
NS
Diet Effect
NS
1

Leptin

TNF-α

IL-6

a

4.6 ± 2.0
b
4.3 ± 1.6
b
4.2 ± 1.8

a

5.1 ± 3.4
a
4.8 ± 3.2
a
4.7 ± 3.7

a

5.4 ± 2.4
ab
5.1 ± 2.1
b
4.3 ± 1.7
P < 0.0001
NS

a

4.3 ± 2.5
a
4.0 ± 2.1
a
3.9 ± 2.4
NS
NS

51.0 ± 30.1
b
36.5 ± 21.8
b
34.2 ± 23.0
55.5 ± 27.5
b
41.7 ± 25.8
b
40.4 ± 25.7
P < 0.0001
NS

sICAM-1

sVCAM-1

a

1.3 ± 3.4
a
1.2 ± 2.9
a
1.2 ± 2.7

a

1.2 ± 2.6
a
1.2 ± 3.0
a
1.2 ± 3.3
NS
NS

a

112 ± 55
b
96 ± 40
b
96 ± 37

a

105 ± 29
ab
99 ± 32
a
103 ± 49
P < 0.001
P < 0.05

a

a

Values are expresses as mean ± SD. Values with different superscripts are significantly different as compared to baseline.
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4. DISCUSSION
A consensus has not been reached regarding the best dietary pattern to alleviate
characteristics of MetS, but the Mediterranean-style pattern has received ample attention
and is considered an effective option (Djoussé, Padilla et al., 2010). The aim of the current
study was to evaluate the impact of a Mediterranean-style, low-glycemic-load diet on body
composition, insulin resistance and inflammation, in a population of women with MetS and
elevated LDL-C. Another objective was to determine if a phytosterol-rich MF provided any
additional benefits to these parameters. Following the 12- week intervention, both groups
showed improvements in body composition, insulin resistance and inflammatory profiles.
Generally, a positive correlation exists between BMI, adiposity and risk for T2D and CVD;
2
therefore, BMI is typically considered a suitable tool to define adult obesity (BMI > 30 kg/m )
and pinpoint individuals that may be at risk of obesity-related morbidity and mortality (2003;
Westphal 2008). BMI is often used as a surrogate marker of overall obesity, while WC is
used to assess central obesity. Both of these measurements are easily obtainable indirect
measurements of obesity (Koopman, Swofford et al., 2009). WC and BMI are strongly
correlated, and elevated WC alone is a strong predictor of mortality and risk for chronic
disease development (Phillips and Prins, 2008; Achike, To et al., 2011). Measurements of
WC are better indicators of body fat distribution, and it is not total body fat, or subcutaneous
fat, but rather, excess intra-abdominal fat that is highly associated with metabolic
abnormalities in overweight and obese individuals (Bjorntorp, 1991; Nielsen and Jensen,
1997; Després, 2006). We previously reported significant reductions in weight and WC for
the participants of this study ( Jones, Fernandez et al., 2011), and here we show that BMI
was significantly reduced in both groups post-intervention. While BMI is a standard indirect
measure of overweight and obesity, it does not distinguish between fat mass and fat free
mass, nor does it describe body fat distribution (Boardley and Pobocik, 2009).
In order to provide a more comprehensive account of changes in body composition over the
course of the intervention, BIA and DEXA measurements were utilized. Results from the BIA
showed that all participants had significant reductions in absolute (kg) and relative (%)
amounts of fat mass while percent free fat mass increased after the intervention. Results
from DEXA assessment revealed significant decreases in body fat and trunk fat, on a
percentage and weight basis. While the decreases in fat mass are desirable, those observed
in fat free mass (specifically lean mass) are less so, but it is acknowledged that body weight
decreased and percent lean increased over time. Abdominal obesity has been considered a
dominant cause of MetS (Després, 2006); therefore, the specific losses in trunk fat may
decrease cardiometabolic risk (Katsoulis, Blaudeau et al., 2009).
Weight loss, and especially abdominal fat loss, has been associated with improvements in
insulin resistance (Weiss, 2007; Bellar, Jarosz, et al., 2008; Aasen, Fagertun et al., 2010). In
a previous study of similar design to the current one, supplementation with a MF and
identical phytochemical-combination increased insulin sensitivity (Lerman, Minich et al.,
2008), it was the expectation that the same observation would be made following this
intervention. While we did measure significant reductions in insulin, and improvements in
HOMA-IR scores, the changes were not statistically different between groups. Insulin
resistance is associated with CVD (Ferrannini, Balkau et al., 2007), and if ignored, can
progress to T2D (Phillips and Prins, 2008). In conjunction with improvements in insulin
resistance, we expected to observe increases in plasma adiponectin, which has insulinsensitizing and anti-inflammatory properties (Matsuzawa, 2010). However, we did not obtain
any significant changes in adiponectin levels for either group. Polak and Shin also reported
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no changes in adiponectin levels, despite weight loss in women (Shin, Yoen Kim, et al.,
2006; Polak, Kovacova et al., 2008). This suggests that other weight loss-associated factors,
in organs other than adipose, may account for the improved insulin variables.
Despite the lack of weight-loss induced change on adiponectin, leptin levels did decrease
significantly in both groups over time. Leptin, an adipokine responsible for increasing energy
expenditure and suppressing food intake (Matsuzawa, 2005), tends to be elevated in obese
individuals, indicative of leptin resistance (Gade, Schmit et al., 2010; Münzberg, 2010).
Therefore, the decreases observed may suggest improved sensitivity to leptin. The
significant decreases observed in trunk fat may also contribute to the reductions in plasma
levels of TNF-α. In an obese state, adipocyptes can overproduce cytokines such as TNF-α
and IL-6 (Jensen, 2006). These molecules in turn recruit monocytes to the adipose tissue
and facilitate their differentiation to active macrophages, which can produce more proinflammatory molecules, intensifying the systemic metabolic dysfunction associated with
obesity (Ouchi, Parker et al., 2011; Vykoukal and Davies, 2011). We did not observe
substantial changes in IL-6, but the reductions in TNF-α are indicative of a less inflammatory
profile. Another marker of inflammation, and more specifically of endothelial function, sICAM1 was also reduced, but only in the MF group. ICAM-1 responds to inflammatory conditions
and mediates the migration of leukocytes into tissues (Hubbard and Rothlein, 2000). There
is a tendency for ICAM-1 to be elevated in obesity, and it has been positively correlated with
central adiposity and insulin resistance (Straczkowski, Lewczuk et al., 2002; Leinonen, HurtCamejo et al., 2003). In agreement with the similar reductions we recorded in abdominal fat
and insulin resistance for both groups, the decreases in sICAM-1 were expected regardless
of group distribution. However, we only observed changes in the MF for this variable. VCAM1, another marker of endothelial function was not significantly modified in either group
following the intervention.
We acknowledge the limitation of only utilizing DEXA, the gold-standard to assess body
composition, for a subset of study participants. It may also have been beneficial to assess
adiponectin levels using a more sensitive assay, such as an ELISA, but sample availability
made this unfeasible.

5. CONCLUSIONS
Overall, following the 12-week intervention, BMI decreased significantly in both groups, but
2
not enough on average to remove participants from the obese category (BMI > 30 kg/m ).
However, direct analysis of body composition, with BIA and DEXA, revealed significant
decreases in abdominal fat mass. These data, in combination with the previously reported
WC information (Jones, Fernandez et al., 2011), substantiate the possible benefits of a
Mediterranean-style dietary pattern for obesity treatment, and more specifically for visceral
adipose reduction. Furthermore, insulin resistance and leptin sensitivity were improved in all
participants. The MF appeared to improve endothelial function, as evidenced by the
reductions in sICAM-1, which were not observed in the control group. In total, adherence to
a low-glycemic-load, Mediterranean-style diet appears to positively influence body
composition and insulin resistance in women with MetS and elevated LDL-C.
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